Evidence map›Paper›PMID 33169196›Full record

ReviewVirchows Archiv : an international journal of pathology2021

Molecular approach to the classification of chronic fibrosing lung disease-there and back again.

Stijn E Verleden, Peter Braubach, Mark Kuehnel, Nicolas Dickgreber, Emily Brouwer, Pauline Tittmann, Florian Laenger, Danny Jonigk

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Stijn E VerledenInstitute of Pathology, Hannover Medical School, Hannover, Germany. Stijn.verleden@kuleuven.be.ORCID http://orcid.org/0000-0002-9656-5844
Peter BraubachInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Mark KuehnelInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Nicolas DickgreberDepartment of Respiratory Medicine and Thoracic Oncology, Ibbenbueren General Hospital, Ibbenbueren, Germany.
Emily BrouwerInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Pauline TittmannInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Florian LaengerInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Danny JonigkInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DE

Funding

European Research Council 771883Fonds Wetenschappelijk Onderzoek 12G8718NFonds Wetenschappelijk Onderzoek V441019N
6 · The paper itself

Abstract

Chronic diffuse parenchymal lung disease (DPLD) is an umbrella term for a very heterogeneous group of lung diseases. Over the last decades, clinical, radiological and histopathological criteria have been established to define and separate these entities. More recently the clinical utility of this approach has been challenged as a unifying concept of pathophysiological mechanisms and a shared response to therapy across the disease spectrum have been described. In this review, we discuss molecular motifs for subtyping and the prediction of prognosis focusing on genetics and markers found in the blood, lavage and tissue. As a purely molecular classification so far lacks sufficient sensitivity and specificity for subtyping, it is not routinely used and not implemented in international guidelines. However, a better molecular characterization of lung disease with a more precise identification of patients with, for example, a risk for rapid disease progression would facilitate more accurate treatment decisions and hopefully contribute to better patients' outcomes.

Indexed as

BiomarkersDisease ProgressionFibrosisHumansLungLung Diseases, InterstitialPrognosisBiomarkersBiomarkerDiffuse parenchymal lung diseaseIdiopathic pulmonary fibrosisInterstitial lung diseaseLung fibrosis

Identifiers

PMID33169196
OpenAlexW3100572204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.